Phase 3 results revealed Monday led shares to surge and should yield an approval application in IgA nephropathy, a ...

Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

Two great examples are Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B) and Vertex Pharmaceuticals (NASDAQ: VRTX). Warren ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

UBS analyst Eliana Merle reaffirmed a Buy rating and a $582 price target for Vertex Pharmaceuticals, praising the adoption of ...

Five Indian-origin women and an Indian woman have been named in Fortune’s 2025 Most Powerful Women list. The list is topped ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the ...